AlphaStocks

GILD vs HRMY

As of Sep 20, 2026, Gilead Sciences (GILD) scores 6.4/10 and Harmony Biosciences Holdings (HRMY) 7.5/10 on AlphaStocks' five-model composite, so HRMY scores higher. GILD trades 21% below its model fair value.

GILD

GILEAD SCIENCES, INC.

6.4

Consider Buy

$149.99

HRMY

Harmony Biosciences Holdings, Inc.

7.5

Strong Buy

$42.06

GILD vs HRMY: Which is the Better Investment?

GILEAD SCIENCES, INC. (GILD) scores 6.4/10 while Harmony Biosciences Holdings, Inc. (HRMY) scores 7.5/10 on AlphaStocks' composite model. Harmony Biosciences Holdings, Inc. has the higher composite rating of Strong Buy. On a P/E basis, Harmony Biosciences Holdings, Inc. trades at 15.5x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricGILDHRMY
Scores & Fundamentals
Composite Score6.4/107.5/10
RatingConsider BuyStrong Buy
Price$149.99$42.06
P/E Ratio22.115.5
ROE38.5%18.6%
Market Cap$188B$2B
Fair Value$190.01
Dividend Yield2.5%
Sector Rank#30 of 168#5 of 168
Model Verdicts
PiotroskiStrongAttractive
BuffettStrongAttractive
GrahamCautionNeutral
LynchNeutralStrong
GreenblattAttractiveStrong
View full GILDanalysis →View full HRMYanalysis →

Related comparisons

Compare any two stocks →

GILD vs HRMY: Which Stock Scores Higher?

GILEAD SCIENCES, INC. (GILD) and Harmony Biosciences Holdings, Inc. (HRMY) are both in the Health Care sector. HRMY currently leads with a composite score of 7.5/10 (Strong Buy) compared to GILD's 6.4/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer